The effect on plasma potassium of a combined preparation of frusemide and slow-release potassium chloride (Diumide-K Continus tablets).
An open trial was carried out on ten middle-aged and elderly patients in cardiac failure to assess the effect on plasma potassium levels of one or more tablets containing 40 mg frusemide and a controlled-release formulation containing 600 mg potassium chloride. Patients had previously been maintained on frusemide and potassium supplements given as separate tablets. No significant rise or fall was observed when treatment was changed to the combined tablet.
D000284:Administration, Oral; D000368:Aged; D003692:Delayed-Action Preparations; D005260:Female; D005665:Furosemide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood*; D011189:Potassium Chloride / Q000008:administration & dosage* / Q000627:therapeutic use
D003692:Delayed-Action Preparations; D011189:Potassium Chloride; D005665:Furosemide; D011188:Potassium